Literature DB >> 29111815

Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents.

Peizeng Yang1, Zi Ye1, Liping Du1, Qingyun Zhou1, Jian Qi1, Liang Liang1, Lili Wu1, Chaokui Wang2, Aize Kijlstra2.   

Abstract

PURPOSE: To investigate the effectiveness, visual outcome, and prognostic factors of Vogt-Koyanagi-Harada (VKH) disease treatment with a reduced dose of corticosteroids combined with immunosuppressive agents.
METHODS: The clinical characteristics, auxiliary examinations, treatment result, visual outcome, and prognostic factors in VKH patients were analyzed.
RESULTS: A total of 998 VKH patients were divided into posterior uveitis group (Group1), anterior uveal involvement group (Group 2), and recurrent granulomatous anterior uveitis group (Group 3). Reduced doses of corticosteroids combined with immunosuppressive agents were used for 1-1.5 years. Uveitis was controlled in 100%, 100%, and 96.8% of these three groups, respectively. Visual improvement and stability was observed in 98.1%, 96.5%, and 88.3%, respectively. Treatment after disease onset, visual acuity at first visit, and 1 month after treatment was positively associated with BCVA at last visit (p < 0.05).
CONCLUSION: A reduced dose of corticosteroids combined with immunosuppressive agents effectively controlled the intraocular inflammation and improved visual acuity in most Chinese VKH patients.

Entities:  

Keywords:  Prognosis factor; Treatment regimen; VKH disease

Mesh:

Substances:

Year:  2017        PMID: 29111815     DOI: 10.1080/02713683.2017.1383444

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  10 in total

1.  Development and Evaluation of Diagnostic Criteria for Vogt-Koyanagi-Harada Disease.

Authors:  Peizeng Yang; Yuanyuan Zhong; Liping Du; Wei Chi; Ling Chen; Rui Zhang; Meifen Zhang; Hong Wang; Hong Lu; Liu Yang; Wenjuan Zhuang; Yan Yang; Lin Xing; Lei Feng; Zhengxuan Jiang; Xiaomin Zhang; Yuqin Wang; Hui Zhong; Liqiong Jiang; Changlin Zhao; Fuzhen Li; Shuang Cao; Xiaoli Liu; Xuan Chen; Yanyun Shi; Weizhong Zhao; Aize Kijlstra
Journal:  JAMA Ophthalmol       Date:  2018-09-01       Impact factor: 7.389

2.  Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.

Authors:  Massimo Accorinti; Maria Carmela Saturno; Ludovico Iannetti; Priscilla Manni; Davide Mastromarino; Maria Pia Pirraglia
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

3.  Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline.

Authors:  Guangyao Li; Ningli Wang; Yu Zhang; Wenbin Wei; Hai Lu; Suodi Zhai; Chao Zhang
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

Review 4.  Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-24

Review 5.  Vogt-Koyanagi-Harada is a Curable Autoimmune Disease: Early Diagnosis and Immediate Dual Steroidal and Non-Steroidal Immunosuppression are Crucial Prerequisites.

Authors:  Ioannis Papasavvas; Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  J Curr Ophthalmol       Date:  2020-12-12

6.  Analyses of circRNA and mRNA Profiles in Vogt-Koyanagi-Harada Disease.

Authors:  Jia Shu; Guannan Su; Jun Zhang; Zhangluxi Liu; Rui Chang; Qingfeng Wang; Peizeng Yang
Journal:  Front Immunol       Date:  2021-12-22       Impact factor: 7.561

7.  Optical Coherence Tomographic Features and Prognostic Values of Macular Edema in Vogt-Koyanagi-Harada Disease.

Authors:  Peng Qin; Zi Ye; Guannan Su; Aize Kijlstra; Peizeng Yang
Journal:  Front Med (Lausanne)       Date:  2022-01-10

8.  Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.

Authors:  Shizhao Yang; Tianyu Tao; Zhaohuai Li; Binyao Chen; Zhaohao Huang; Xiuxing Liu; He Li; Lihui Xie; Wen Feng; Wenru Su
Journal:  Ann Transl Med       Date:  2022-06

Review 9.  Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt-Koyanagi-Harada disease: an updated review.

Authors:  Carl P Herbort; Ilknur Tugal-Tutkun; Ahmed Abu-El-Asrar; Amod Gupta; Masaru Takeuchi; Christine Fardeau; Alireza Hedayatfar; Cristhian Urzua; Ioannis Papasavvas
Journal:  Eye (Lond)       Date:  2021-06-18       Impact factor: 3.775

Review 10.  miRNA Landscape in Pathogenesis and Treatment of Vogt-Koyanagi-Harada Disease.

Authors:  Fabian Vega-Tapia; Mario Bustamante; Rodrigo A Valenzuela; Cristhian A Urzua; Loreto Cuitino
Journal:  Front Cell Dev Biol       Date:  2021-05-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.